CRHR1 encodes corticotropin releasing hormone receptor 1 (CRHR1), a G protein-coupled receptor that binds corticotropin releasing hormone (CRH) and related peptides. It is the primary mediator of the hypothalamic-pituitary-adrenal (HPA) axis response to stress[1]. CRHR1 is widely expressed in brain regions involved in stress, emotion, and memory regulation, including the cortex, hippocampus, amygdala, and pituitary gland. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration and neuropsychiatric disorders.
CRHR1 encodes corticotropin releasing hormone receptor 1 (CRHR1), a G protein-coupled receptor that binds CRH and related peptides with high affinity. It is the primary mediator of the hypothalamic-pituitary-adrenal (HPA) axis response to stress[1:1]. In the brain, CRHR1 regulates stress responses, anxiety, mood, and cognitive function through signaling in the cortex, hippocampus, amygdala, and other limbic structures. Dysregulated CRHR1 signaling has been implicated in major depression, anxiety disorders, post-traumatic stress disorder (PTSD), and Alzheimer's disease[2][3]. CRHR1 antagonists have been investigated as treatments for depression and anxiety disorders, though clinical efficacy has been variable.
CRHR1 is a 444-amino acid G protein-coupled receptor (GPCR) belonging to the secretin family (Class B)[4]. The receptor consists of:
Upon CRH binding, CRHR1 activates Gαs, leading to increased adenylate cyclase activity and elevated intracellular cAMP[4:1]. This triggers protein kinase A (PKA) activation and downstream phosphorylation of target proteins.
CRHR1 mediates multiple physiological functions[5]:
CRHR1 has been extensively studied in major depressive disorder (MDD)[6]. Key findings include:
The dysregulation of the CRH-CRHR1 system in depression suggests that normalizing this pathway may have therapeutic benefit[7].
CRHR1 plays a central role in anxiety disorders[8]:
CRHR1 antagonists have been developed as potential anxiolytic agents[9], though clinical translation has been challenging.
CRHR1 is implicated in PTSD pathophysiology[10]:
CRHR1 has been increasingly recognized in Alzheimer's disease pathophysiology[3:1][11]:
CRHR1 is expressed in multiple brain regions and peripheral tissues[4:2]:
Brain regions (highest expression):
Peripheral tissues:
The widespread expression pattern reflects the diverse physiological roles of CRHR1 beyond the HPA axis.
Several CRHR1 antagonists have been developed and tested in clinical trials[14]:
Clinical challenges:
Holsboer F, Ising M. Central CRH system in depression and anxiety disorders. Journal of Psychopharmacology. 2003. ↩︎ ↩︎ ↩︎
Arimi H, et al. CRHR1 polymorphisms and susceptibility to major depression. Journal of Affective Disorders. 2014. ↩︎ ↩︎
Lopez-Fernandez MA, et al. CRH and CRHR1 in Alzheimer's disease pathophysiology. Journal of Alzheimer's Disease. 2018. ↩︎ ↩︎ ↩︎
Webster EL, et al. CRHR1 receptor: from cloning to function. Brain Research. 2001. ↩︎ ↩︎ ↩︎ ↩︎
Herbert J, et al. Corticotropin-releasing hormone, stress and brain function. Cerebral Cortex. 2013. ↩︎ ↩︎
Chen Y, et al. CRHR1 and HPA axis dysregulation in major depressive disorder. Psychoneuroendocrinology. 2014. ↩︎
Zobel A, et al. Effects of high-affinity CRF antagonist on psychotherapy-resistant depression. Journal of Psychiatric Research. 2000. ↩︎ ↩︎
Davis M, et al. CRHR1 and the neural circuitry of fear and anxiety. Nature Reviews Neuroscience. 2019. ↩︎
Smith KL, et al. Targeting CRHR1 in anxiety disorders: recent progress. Neuropharmacology. 2015. ↩︎ ↩︎
Brázdi A, et al. CRHR1 gene variants and stress response in PTSD. Journal of Traumatic Stress. 2018. ↩︎ ↩︎
Ryu S, et al. CRHR1 and stress-related neuropathology in Alzheimer's disease. Neurobiology of Aging. 2018. ↩︎ ↩︎
Rao R, et al. CRHR1 mediates stress-induced synaptic dysfunction. Journal of Neuroscience. 2012. ↩︎ ↩︎
Liu Z, et al. CRHR1 signaling in neuroinflammation and Alzheimer's disease. GLIA. 2017. ↩︎
Martinez C, et al. CRHR1 antagonists as novel antidepressant agents. Pharmacological Reviews. 2019. ↩︎